MERS coronavirus vaccine
AssigneeCureVac AG
InventorSusanne Rauch
Life of this patent
Estimating the term…
Abstract
The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.
Claims10
A method of treatment or prophylaxis of Middle East respiratory syndrome (MERS) coronavirus infections comprising the steps:
- a) providing a composition comprising a mRNA comprising at least one coding region, encoding an antigenic protein comprising a spike protein (S) of a Middle East respiratory (MERS) coronavirus, said coding sequence being at least 90% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 2373, 2374, 2375, 2376, 2377 and 2378, wherein the mRNA is associated with lipid nanoparticles (LNPs);
- and
- b) administering an effective amount of the composition to an organism, thereby stimulating a humoral immune response to the antigenic protein in the organism.
Dependencies are inferred from the claim text.